uniQure N.V. QURE
Nov 10, 2026, 2:38 PM EST
- YTD
- -6.16%
- 1 year
- -14.13%
- Market cap
- 1.57B
- Revenue (ttm)
- 20.17M
- EPS (ttm)
- -3.51
- Shares out
- 70.14M
- Forward P/E
- -7.14
- YTD return
- -6.16%
- 1-year return
- -14.13%
- Volume
- 581.06K
- Avg volume
- 2.17M
- Open
- 22.45
- Previous close
- 22.79
- Day's range
- 22.24 – 23.72
- 52-week range
- 8.73 – 51.72
- Beta
- 1.13
- Analysts
- Strong Buy
- Price target
- 60.21 (+168.1%)
- Earnings date
- Mar 1, 2027
5D -0.35 (-1.47%)
Key statistics
- Enterprise value
- 1.41B
- PEG ratio
- 0.00
- Price / sales
- 79.26
- Price / book
- 5.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 40.40%
- Free cash flow
- -167.19M
- Total cash
- 668.46M
- Total debt
- 559.64M
- Return on equity
- -88.99%
- Short % of float
- 12.62%
- 50-day average
- 31.86
- 200-day average
- 29.66
Analyst view
Consensus: strong buy
- Target (low)
- 28.01
- Target (mean)
- 60.21
- Target (high)
- 91.68
- Strong buy1
- Buy10
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.745.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.88 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.91539 | -0.88 | +0.04 | +3.87% |
| Jul 29, 2026 | Jun 30, 2026 | -0.82228 | -1.22 | -0.40 | -48.37% |
| May 5, 2026 | Mar 31, 2026 | -0.88 | -0.85 | +0.03 | +3.41% |
| Mar 2, 2026 | Dec 31, 2025 | -0.93 | -0.56 | +0.37 | +39.78% |
| Nov 10, 2025 | Sep 30, 2025 | -0.85 | -1.38 | -0.53 | -62.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Barclays | down | Overweight | Equal-Weight |
| Oct 2, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 30, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 30, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Jul 30, 2026 | Barclays | main | Overweight | Overweight |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- uniqure.com
News
uniQure Q3 Earnings Call Highlights 
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript 
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates 
uniQure Q3 2026 Earnings Call Transcript 
uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate 
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update 
uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade) 
FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals 
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28 
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48
Your note
Sign in to keep a note on QURE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABI-SAAB WALID | Officer | Conversion of Exercise of derivative security | Jun 29, 2026 | 148,235 |
| BALACHANDRAN MADHAVEN | Director | Conversion of Exercise of derivative security | Jun 16, 2026 | 43,254 |
| JACQUES RACHELLE SUZANNE | Director | Sale | Jun 10, 2026 | 33,903 |
| KAPUSTA MATTHEW C | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 519,227 |
| KLEMT CHRISTIAN | Chief Financial Officer | Stock Award(Grant) | Mar 3, 2026 | 226,581 |
| MEEK DAVID D | Director | Sale | Jun 10, 2026 | 39,747 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.59% | 6,727,777 | 153.33M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.94% | 4,867,755 | 110.94M | Jun 29, 2026 |
| RTW Investments LP | 5.62% | 3,941,572 | 89.83M | Jun 29, 2026 |
| State Street Corporation | 4.14% | 2,903,825 | 66.18M | Jun 29, 2026 |
| Aberdeen Group plc | 4.06% | 2,848,117 | 64.91M | Jun 29, 2026 |
| Blackrock Inc. | 2.68% | 1,877,453 | 42.79M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90% | 2,031,760 | 46.30M | Sep 29, 2026 |
| abrdn Healthcare Investors | 1.77% | 1,240,256 | 28.27M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.76% | 1,237,920 | 28.21M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.37% | 959,052 | 21.86M | Jun 29, 2026 |
| abrdn World Healthcare Fund | 1.13% | 792,575 | 18.06M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 758,041 | 17.28M | Jun 29, 2026 |